2,815 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Advisory Alpha LLC

Advisory Alpha LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 2,815 shares of the biopharmaceutical company’s stock, valued at approximately $260,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. XML Financial LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter worth about $203,000. Genesis Private Wealth LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter worth about $362,000. Simon Quick Advisors LLC increased its position in shares of Gilead Sciences by 24.7% during the 4th quarter. Simon Quick Advisors LLC now owns 6,120 shares of the biopharmaceutical company’s stock worth $565,000 after purchasing an additional 1,214 shares during the last quarter. MCF Advisors LLC increased its position in shares of Gilead Sciences by 45.2% during the 4th quarter. MCF Advisors LLC now owns 6,779 shares of the biopharmaceutical company’s stock worth $626,000 after purchasing an additional 2,111 shares during the last quarter. Finally, Fort Washington Investment Advisors Inc. OH grew its position in Gilead Sciences by 16.6% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 376,047 shares of the biopharmaceutical company’s stock valued at $34,735,000 after acquiring an additional 53,617 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Piper Sandler lifted their target price on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Wolfe Research assumed coverage on Gilead Sciences in a research report on Friday, November 15th. They issued an “outperform” rating and a $110.00 target price for the company. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research report on Wednesday, December 11th. BMO Capital Markets lifted their target price on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Finally, Sanford C. Bernstein initiated coverage on Gilead Sciences in a research report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 target price for the company. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $97.96.

Gilead Sciences Price Performance

GILD stock opened at $92.92 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The business has a 50 day moving average price of $91.63 and a 200 day moving average price of $84.63. The stock has a market cap of $115.80 billion, a price-to-earnings ratio of 1,032.44, a PEG ratio of 1.31 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter in the previous year, the business earned $2.29 earnings per share. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. Equities research analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.31%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. The trade was a 20.44 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 456,234 shares of company stock worth $42,130,461. 0.16% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.